Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

NCT01365611 | Completed Phase 1 Results

• 1 other identifier: ROX 2006-04
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

This was a non-randomized, open label study in healthy male and female volunteers. A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6; in addition, subjects received a daily intranasal dose of 200 µg fluticasone propionate on Days 2-6. Subjects remained resident in the Clinical Unit from the evening of Day 1 until the morning of Day 2 and from the evening of Day 5 until the morning of Day 7, and made ambulatory visits to the Clinical Unit on the morning of Days 3-5. A post study medical was performed within 7 days of study completion. The objective of this study was to assess the effects of chronic administration of fluticasone propionate on the pharmacokinetics of intranasal ketorolac in healthy male and female subjects.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (6)

• Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine)

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

• Tmax (the Time to Maximum Concentration of Ketorolac Tromethamine)

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

• AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose of Ketorolac Tromethamine).

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

• AUC Inf (the AUC From Time Zero to Infinity, Where Possible)

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

• t1/2z (the Terminal Half-life of Ketorolac Tromethamine, Where Possible)

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

• MRT (the Mean Residence Time of Ketorolac Tromethamine, Where Possible)

  PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6

Study Arms (1)

Ketorolac tromethamine

EXPERIMENTAL

Drug: Ketorolac tromethamine; Drug: Fluticasone Propionate

Interventions

Ketorolac tromethamine DRUG

A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.

Ketorolac tromethamine

Fluticasone Propionate DRUG

Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6

Ketorolac tromethamine

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female volunteers aged 18 to 60 years inclusive
• Female subjects of child bearing potential must have had a negative urine pregnancy test prior to entry into the study and must not have been breastfeeding
• All male subjects with female partners of child bearing potential must have consented to use a medically acceptable method of contraception (oral or implanted contraceptive hormones, intrauterine device or surgical sterilization plus condom or diaphragm with spermicidal agent) throughout the study period
• Subject must have given signed informed consent
• Subject was within 20% of the normal weight for his/her height and body build according to the table of "Desirable Weights for Men and Women" (Metropolitan Life Insurance Co. 1999)
• Subject's medical history was considered normal, with no clinically significant abnormalities
• Subject was considered to be in good health in the opinion of the Investigator as determined by a pre-study physical examination with no clinically significant abnormalities, vital signs within normal ranges and an electrocardiogram (ECG) with no clinically significant abnormalities
• Subject's pre study clinical laboratory findings were within the normal range or if outside of the normal range were not deemed clinically significant in the opinion of the Investigator
• Subject had bilateral patent nasal airways at screening and Day 1 as assessed by the Investigator
• Subject had a body weight of at least 60 kg

You may not qualify if:

• Subject had had a clinically significant illness in the 4 weeks before screening
• Subject had used prescribed medications in the 3 weeks prior to dosing or over-the-counter preparations for 7 days prior to dosing, except paracetamol which was allowed up to 48 h prior to dosing. However, use of multivitamins and oral contraceptives was permitted
• Subject had a significant history of drug/solvent abuse, or a positive drugs of abuse (DOA) test at screening
• Subject had a history of alcohol abuse or currently drank in excess of 28 units per week (males) or 21 units per week (females)
• Subject was a current user of tobacco or had a history of smoking in the past 5 years
• Subject was in the opinion of the Investigator not suitable to participate in the study
• Subject had participated in any clinical study with an investigational drug/device within 3 months prior to dosing
• Subject had a positive result of human immunodeficiency virus (HIV) screen, hepatitis B screen or hepatitis C screen
• Subject had had a serious adverse reaction or significant hypersensitivity to any drug
• Subject had donated 500 mL or more of blood within the 3 months prior to screening
• Subject had any history of co-existing nasal polyps, nonsteroidal anti-inflammatory drug (NSAID) sensitivity and asthma
• Subject had had an allergic reaction to aspirin or other NSAIDs
• Subject had a current upper respiratory tract infection or other respiratory tract condition that could interfere with the absorption of the nasal spray or with the assessment of adverse events (AEs)
• Any suspicion of rhinitis medicamentosa (chronic daily use of topical decongestants)
• Subject had used a monoamine oxidase inhibitor in the 14 days prior to study entry

Sponsors & Collaborators

• Egalet Ltd: lead

Study Sites (1)

ICON Development Solutions

Manchester, United Kingdom

Location

MeSH Terms

Interventions

Ketorolac Tromethamine; Fluticasone

Intervention Hierarchy (Ancestors)

Indomethacin; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Androstadienes; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Results Point of Contact

• Title: David Bregman, M.D., Ph.D.
• Organization: Luitpold Pharmaceuticals, Inc.

dbregman@lpicrd.com

610-650-4200

Study Officials

• Cyril Clarke, BSc MB BS MFPM

  ICON Development Solutions

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 1, 2011
• First Posted: June 3, 2011
• Study Start: February 1, 2007
• Primary Completion: May 1, 2007
• Study Completion: March 1, 2008
• Last Updated: March 15, 2017
• Results First Posted: April 30, 2013

Record last verified: 2017-02

Locations

GB (1)